Abstract
•Several variables are related to insulin production in persons with T2D treated with MDI.•Longer T2D duration and more glycaemic variability is associated with lower insulin production.•Degree of insulin production is an essential factor to determine whether CGM/FGM is needed.
From the MDI-liraglutide study, we evaluated variables associated with endogenous insulin production in persons with multiple daily insulin injections-treated type 2 diabetes by relating C-peptide, proinsulin and proinsulin/C-peptide ratio at baseline to baseline variables. Lower insulin production was related to longer diabetes duration, shorter abdominal sagittal diameter and more glycaemic variability.